palmitoylethanolamide.com.au
HomeResearchMichael 2022

Review of Alzheimer's disease drugs and their relationship with neuron-glia interaction

Michael Kunle Ajenikoko, Abayomi Oyeyemi Ajagbe, Oluwanisola Akanji Onigbinde, Akeem Ayodeji Okesina, Ahmad Adekilekun Tijani. IBRO Neurosci Rep. 2022 Nov 19:14:64-76.

ReviewHumansOther animals

Design
Review
Subjects
Not applicable; a narrative review
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
How Alzheimer's disease drugs, including palmitoylethanolamide, act on neuron-astrocyte-microglia interactions: pharmacokinetics, mechanism, dosing and clinical presentation across donepezil, choline alphoscerate, galantamine, dextromethorphan, palmitoylethanolamide, citalopram, resveratrol and solanezumab.

What the authors reported

The abstract gives no specific findings on palmitoylethanolamide. The authors summarise donepezil, choline alphoscerate, galantamine, dextromethorphan, palmitoylethanolamide, citalopram, resveratrol and solanezumab by pharmacokinetics, mechanism, dosing and clinical presentation.

Limits of this study

A narrative review, not new data. The abstract gives no detail on PEA evidence. The authors declare no conflict of interest.

Source

PubMed 36593897 · doi:10.1016/j.ibneur.2022.11.005

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.